Centre de Référence Maladies Rares

U1035 INSERM

Biothérapie des Maladies Génétiques Inflammatoires et Cancers (BMGIC)

FR : Biologie Fondamentale Appliquée à la Médecine

U1035Afficher le menu agenda FR / EN

Prochains rendez-vous

Réunions hebdomadaires des équipes de l'unité U1035

1er trimestre 2016

afficher le planning afficher par mois

Conference Robert Ballottii

Le 24 novembre 2016 de 11:00 à 17:00.

“Melanoma Initiating Cells, Senescence and Resistance: MITF Takes the Central Stage”

Robert Ballotti Inserm U1065, est invité par Pr taieb, pour nous cette conférence, salle de conférences de l’IBGC, site de Carreire zone sud, université de Bordeaux.

Among several hypotheses that might explain the resistance of melanoma to current therapies, one of the trendiest
suggests the existence of a poorly differentiated melanoma cell population that would also account for the well
recognized melanoma heterogeneity and invasiveness. This population, which displays an increase in mesenchymal
and stemness phenotypes, can be referred as Melanoma Initiating Cells (MIC). Previous works, including ours,
identified a low-MITF population endowed with all the properties of MIC, but in the absence of surface marker a full
characterization of this population was not possible.
To overcome this hurdle, we engineered, using homologous recombination, a melanoma cell model expressing a
MCherry flag upstream the exon 1 of the M-MITF. Using these cells, we have been able to isolate live LowMCherry/low-MITF
cells and to confirm their high tumorigenic potential, as well as their resistance to BRAF inhibitors.
DNA microarray analysis of Low-Mcherry vs High Mcherry allowed us to identify a repertoire of genes overexpressed in
the MIC that is different from that found in after MITF silencing. Among these genes several surface markers were
identified and we focused our attention on 2 of them; NGFR/CD271 that was already associated with MIC and ITGBL1 a
poorly studied member of integrin family.
Finally, preliminary analysis of the histone methylation/acetylation marks in Low-MITF vs High-MITF cells involves
epigenetic regulation in the control of the phenotypic switch between MIC and their differentiated progeny.
In summary, our data brought new insight into molecular mechanisms controlling melanoma cell plasticity,
tumorigenicity and resistance to drugs. Further investigations, will allow evaluating the importance these surface
markers and epigenetic modifications in melanoma treatment.

Conférence Francoise Pflumio

Le 22 novembre 2016 de 11:00 à 15:00.

"Interactions between T-ALL and the BM microenvironment influence the leukemic development and the resistance to certain drugs"

Francoise Pflumio , CEA - Laboratoire des cellules Souches Hématopoïétiques et des Leucémies – LSHL
Salle de conférences de l’IBGC, site de Carreire zone sud, université de Bordeaux

T-cell acute lymphoblastic leukemia (T-ALL) is a T-cell progenitor malignancy, which mainly
affects children and young adults. In T-ALL development, leukemic cells home to various
bone marrow (BM) sites that include adipocyte-poor (red marrow) and adipocyte-rich (yellow
marrow) niches. Using xenografts of human and mouse T-ALL, we explored the impact of
these distinct BM sites on leukemic cells. We demonstrate that T-ALL cells invade all studied
BM sites but with different kinetics depending on those sites. T-ALL cells also displayed BMniche
specific characteristics in terms of cell surface phenotype, metabolism, cell cycle
progression albeit genomic abnormalities were similar wherever the T-ALL cells were isolated
from. Overall, our current results demonstrate that distinct BM sites differentially orchestrate
T-ALL development and during my talk I will also show how such BM niches may participate
into chemo-resistance.

Equipe Mircade

Le 07 novembre 2016 de 14:30 à 16:30.

Répétition thèse Antonin Bourdieu.

Equipe Mircade

Le 03 novembre 2016 de 10:00 à 12:00.

Répétition de thése Emilie Indersie

Reunion Equipe CSHNL Annulé

Le 24 octobre 2016 de 14:30 à 16:30.

Equipe Immuno-Dermato

Le 17 octobre 2016.

Equipe Mircade

Le 10 octobre 2016 de 14:30 à 16:30.

Equipe Dermato

Le 03 octobre 2016 de 14:30 à 16:30.

Equipe Biothérapie

Le 26 septembre 2016 de 14:30 à 16:30.

Equipe Mircade

Le 19 septembre 2016 de 14:30 à 16:30.

Equipe Dermato

Le 12 septembre 2016 de 14:30 à 16:30.

MirCaDe, réunion de février

Le 29 février 2016 de 14:30 à 16:30.

La réunion a lieu au laboratoire, salle habituelle.
Ordre du jour : état des lieux recherche.

HÉMATO

Le 22 février 2016 de 14:30 à 16:30.

DERMATO

Le 15 février 2016 de 14:30 à 16:30.

MirCaDe

Le 08 février 2016 de 14:30 à 16:30.

DERMATO

Le 01 février 2016 de 14:30 à 16:30.

HÉMATO

Le 25 janvier 2016 de 14:30 à 16:30.

MirCaDe

Le 18 janvier 2016 de 14:30 à 16:30.

BIOTHÉRAPIES

Le 11 janvier 2016 de 14:30 à 16:30.

ATIP

Le 04 janvier 2016 de 14:30 à 16:30.

DERMATO

Le 14 décembre 2015 de 14:30 à 16:30.

IMPORTANT !

Les chefs d’équipe sont responsables de l’organisation des réunions.

INSERM U1035! - Université de Bordeaux
Work
146 rue Léo Saignat - Bât. TP zone sud, 4ème étage
33000 Bordeaux
Aquitaine
France
Work 0557 57 13 73/74
contact@u1035-inserm.fr